Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Transfer Clinical Study in X-Linked Myotubular Myopathy (ASPIRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03199469
Recruitment Status : Active, not recruiting
First Posted : June 27, 2017
Last Update Posted : March 10, 2020
Sponsor:
Information provided by (Responsible Party):
Audentes Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and efficacy of AT132 in subjects with X-Linked Myotubular Myopathy aged less than 5 years old. Subjects will receive a single dose of AT132 and will be followed for safety and efficacy for 5 years

Condition or disease Intervention/treatment Phase
X-Linked Myotubular Myopathy Genetic: AT132 Phase 1 Phase 2

Detailed Description:

This study will evaluate safety and efficacy of gene transfer in X-Linked Myotubular Myopathy. Subjects will receive a single dose of AT132 delivered intravenously.

ASPIRO is being conducted in two parts. Part 1 is a dose escalation phase that is evaluating the preliminary safety and efficacy of AT132 at doses of 1x1014 vg/kg and 3x1014 vg/kg. Part 2 of ASPIRO is a pivotal expansion cohort designed to confirm the safety and efficacy of AT132 at a dose of 3x1014 vg/kg. The pivotal expansion cohort will enroll eight subjects, consisting of four age-matched pairs (within +/- 6 months of age). One subject from each pair will be randomized to receive a single dose of AT132 at 3x1014 vg/kg, and the other will serve as a delayed treatment control. Eligible delayed treatment control subjects will be administered AT132 after that individual subject has completed the Week 24 visit as a delayed treatment control.

The primary efficacy endpoint measures will be assessed at Week 24. Subjects will be followed for a total of 5 years after administration of AT132.

This study utilizes an independent Data Monitoring Committee (DMC) that will monitors subject safety and provides recommendations to Audentes regarding dose escalation, dose expansion, and safety matters.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: ASPIRO is being conducted in two parts. Part 1 is a dose escalation phase that is evaluating the preliminary safety and efficacy of AT132 at doses of 1x1014 vg/kg and 3x1014 vg/kg. Part 2 of ASPIRO is a pivotal expansion cohort designed to confirm the safety and efficacy of AT132 at a dose of 3x1014 vg/kg. The pivotal expansion cohort will enroll eight subjects, consisting of four age-matched pairs (within +/- 6 months of age). One subject from each pair will be randomized to receive a single dose of AT132 at 3x1014 vg/kg, and the other will serve as a delayed treatment control. Eligible delayed treatment control subjects will be administered AT132 after that individual subject has completed the Week 24 visit as a delayed treatment control.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients
Actual Study Start Date : August 2, 2017
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1.0 x 10^14 vg/kg
1.0 x 10^14 vg/kg of AT132 delivered intravenously one time
 Genetic: AT132
AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
Experimental: 3.0 x 10^14 vg/kg
3.0 x 10^14 vg/kg of AT132 delivered intravenously one time
 Genetic: AT132
AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
No Intervention: Delayed-Treatment Control
Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Treatment-emergent adverse events (safety and tolerability) [ Time Frame: Baseline through Week 24 ]
    Adverse events, serious adverse events, and laboratory abnormalities (including immunological parameters)

  2. Change from baseline in hours of ventilation support over time through Week 24 [ Time Frame: Baseline to Week 24 ]
    Change in hours of ventilation


Secondary Outcome Measures :
  1. Percentage of subjects achieving functionally independent sitting for at least 30 seconds by Week 24 as assessed by an independent blinded Physical Therapy Adjudication Panel [ Time Frame: Baseline to Week 24 ]
    Achieve functionally independent sitting for at least 30 seconds

  2. Time to reduction in required ventilator support to ≤ 16 hours a day (only in subjects who require invasive ventilation) by Week 24 as assessed by independent blinded Pulmonary Adjudication Panel [ Time Frame: Baseline to Week 24 ]
    Reduction in required ventilator support

  3. Change from baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) by Week 24 [ Time Frame: Baseline to Week 24 ]
    Change in CHOP-INTEND

  4. Change from baseline in maximal inspiratory pressure (PImax) by Week 24 [ Time Frame: Baseline to Week 24 ]
    Change in respiratory endurance

  5. Change from baseline in quantitative analysis of myotubularin expression in the muscle biopsy at Week 24 [ Time Frame: Baseline to Week 24 ]
    Change in myotubularin expression


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Subject has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene as assessed by a Sponsor-approved testing facility.
  • Subject is male.
  • Subject is aged less than 5 years old at Day 1 and/or participated in the ATX-MTM-009 (INCEPTUS) study.
  • Subject requires mechanical ventilatory support:

Part 1: Subject requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full time mechanical ventilation, to noninvasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours).

Part 2: Subject requires invasive mechanical ventilatory support ranging from 20 - 24 hours per day at screening (confirmed by daytime polysomnographic study).

  • Subject requiring invasive mechanical ventilator support is fitted with or willing to be fitted with a cuffed tracheostomy tube for some respiratory assessments.
  • Subject has ventilator maximum positive end-expiratory pressure (PEEP) <8 cm H2O at screening.

Key Exclusion Criteria:

  • Subject is participating in an interventional study designed to treat XLMTM.
  • Subject born <35 weeks gestation who is still not term as per corrected age.
  • Subject tests positive for AAV8 neutralizing antibody with titers above protocol specified threshold.
  • Subject had recent surgery (<3 months before Day 1) or has planned surgery that may confound data collection during the first 48 weeks of the study.
  • Subject has a clinically important condition other than XLMTM in the opinion of the investigator.
  • Subject has a clinically significant underlying liver disease.
  • Subject is currently experiencing a clinically important respiratory infection or other active infection.
  • Subject has received pyridostigmine or any medication to treat XLMTM within 3 months before Day 1.
  • Other than as required per protocol, subject has received immune-modulating agents within 3 months before Day 1 (use of inhaled corticosteroids to manage chronic respiratory conditions is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 4 weeks before dosing.
  • Subject has a contraindication to prednisolone.
  • Subject has a contraindication to study drug or ingredients.
  • Subject has contractures, scoliosis, or other medical condition that would limit the potential to achieve unassisted sitting, in the opinion of the investigator (Part 2 only).
  • Subject is able to sit without assistance for at least 30 seconds at screening, in the opinion of the investigator (Part 2 only).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03199469


Locations
Layout table for location information
United States, California
UCLA Medical Center
Los Angeles, California, United States, 90095
United States, Florida
Powell Center for Rare Disease Research, Univ. of Florida
Gainesville, Florida, United States, 32610
United States, Illinois
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Maryland
National Institute of Neurological Disorders and Stroke/NIH Porter
Bethesda, Maryland, United States, 208892
Canada, Ontario
Hospital for Sick Children
Toronto, Ontario, Canada, M5G0A4
France
Hopital Armad Trousseau
Paris, France, 75012
Germany
Kinderklinik und Kinderpoliklinik im Dr. Von Haunerschen Kinderspital Klinikum der Universitat Munchen
München, Germany, 80337
Sponsors and Collaborators
Audentes Therapeutics
Investigators
Layout table for investigator information
Study Director: Nathan Bachtell, MD Audentes Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Audentes Therapeutics
ClinicalTrials.gov Identifier: NCT03199469    
Other Study ID Numbers: ATX-MTM-002
First Posted: June 27, 2017    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Audentes Therapeutics:
AAV8-Delivered Gene Therapy
XLMTM
Adeno Associated Virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Myopathies, Structural, Congenital
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases